Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods

ABSTRACT Chronic lymphocytic leukemia is the most common hematologic malignancy among adults in Western countries. Several studies show that somatic mutations in the TP53 gene are present in up to 50% of patients with relapsed or refractory chronic lymphocytic leukemia. This study aims to review and compare the methods used to detect somatic TP53 mutations and/or 17p deletions and analyze their importance in the chronic lymphocytic leukemia diagnosis and follow-up. In chronic lymphocytic leukemia patients with refractory or recurrent disease, the probability of clonal expansion of cells with the TP53 mutation and/or 17p deletion is very high. The studies assessed showed several methodologies able to detect these changes. For the 17p deletion, the chromosome G-banding (karyotype) and interphase fluorescence in situ hybridization are the most sensitive. For somatic mutations involving the TP53 gene, moderate or high-coverage read next-generation sequencing and Sanger sequencing are the most recommended ones. The TP53 gene mutations represent a strong adverse prognostic factor for patient survival and treatment resistance in chronic lymphocytic leukemia. Patients carrying low-proportion TP53 mutation (less than 20-25% of all alleles) remain a challenge to these tests. Thus, for any of the methods employed, it is essential that the laboratory conduct its analytical validation, documenting its accuracy, precision and sensitivity/limit of detection.

Saved in:
Bibliographic Details
Main Authors: Chauffaille,Maria de Lourdes L.F., Zalcberg,Ilana, Barreto,Wolney Gois, Bendit,Israel
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) 2020
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792020000300261
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2531-13792020000300261
record_format ojs
spelling oai:scielo:S2531-137920200003002612020-09-16Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methodsChauffaille,Maria de Lourdes L.F.Zalcberg,IlanaBarreto,Wolney GoisBendit,Israel Chronic lymphocytic leukemia TP53 mutations 17p deletions ABSTRACT Chronic lymphocytic leukemia is the most common hematologic malignancy among adults in Western countries. Several studies show that somatic mutations in the TP53 gene are present in up to 50% of patients with relapsed or refractory chronic lymphocytic leukemia. This study aims to review and compare the methods used to detect somatic TP53 mutations and/or 17p deletions and analyze their importance in the chronic lymphocytic leukemia diagnosis and follow-up. In chronic lymphocytic leukemia patients with refractory or recurrent disease, the probability of clonal expansion of cells with the TP53 mutation and/or 17p deletion is very high. The studies assessed showed several methodologies able to detect these changes. For the 17p deletion, the chromosome G-banding (karyotype) and interphase fluorescence in situ hybridization are the most sensitive. For somatic mutations involving the TP53 gene, moderate or high-coverage read next-generation sequencing and Sanger sequencing are the most recommended ones. The TP53 gene mutations represent a strong adverse prognostic factor for patient survival and treatment resistance in chronic lymphocytic leukemia. Patients carrying low-proportion TP53 mutation (less than 20-25% of all alleles) remain a challenge to these tests. Thus, for any of the methods employed, it is essential that the laboratory conduct its analytical validation, documenting its accuracy, precision and sensitivity/limit of detection.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)Hematology, Transfusion and Cell Therapy v.42 n.3 20202020-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792020000300261en10.1016/j.htct.2020.05.005
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Chauffaille,Maria de Lourdes L.F.
Zalcberg,Ilana
Barreto,Wolney Gois
Bendit,Israel
spellingShingle Chauffaille,Maria de Lourdes L.F.
Zalcberg,Ilana
Barreto,Wolney Gois
Bendit,Israel
Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods
author_facet Chauffaille,Maria de Lourdes L.F.
Zalcberg,Ilana
Barreto,Wolney Gois
Bendit,Israel
author_sort Chauffaille,Maria de Lourdes L.F.
title Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods
title_short Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods
title_full Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods
title_fullStr Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods
title_full_unstemmed Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods
title_sort detection of somatic tp53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods
description ABSTRACT Chronic lymphocytic leukemia is the most common hematologic malignancy among adults in Western countries. Several studies show that somatic mutations in the TP53 gene are present in up to 50% of patients with relapsed or refractory chronic lymphocytic leukemia. This study aims to review and compare the methods used to detect somatic TP53 mutations and/or 17p deletions and analyze their importance in the chronic lymphocytic leukemia diagnosis and follow-up. In chronic lymphocytic leukemia patients with refractory or recurrent disease, the probability of clonal expansion of cells with the TP53 mutation and/or 17p deletion is very high. The studies assessed showed several methodologies able to detect these changes. For the 17p deletion, the chromosome G-banding (karyotype) and interphase fluorescence in situ hybridization are the most sensitive. For somatic mutations involving the TP53 gene, moderate or high-coverage read next-generation sequencing and Sanger sequencing are the most recommended ones. The TP53 gene mutations represent a strong adverse prognostic factor for patient survival and treatment resistance in chronic lymphocytic leukemia. Patients carrying low-proportion TP53 mutation (less than 20-25% of all alleles) remain a challenge to these tests. Thus, for any of the methods employed, it is essential that the laboratory conduct its analytical validation, documenting its accuracy, precision and sensitivity/limit of detection.
publisher Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
publishDate 2020
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792020000300261
work_keys_str_mv AT chauffaillemariadelourdeslf detectionofsomatictp53mutationsand17pdeletionsinpatientswithchroniclymphocyticleukemiaareviewofthecurrentmethods
AT zalcbergilana detectionofsomatictp53mutationsand17pdeletionsinpatientswithchroniclymphocyticleukemiaareviewofthecurrentmethods
AT barretowolneygois detectionofsomatictp53mutationsand17pdeletionsinpatientswithchroniclymphocyticleukemiaareviewofthecurrentmethods
AT benditisrael detectionofsomatictp53mutationsand17pdeletionsinpatientswithchroniclymphocyticleukemiaareviewofthecurrentmethods
_version_ 1756442062098530304